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Abstract
Background Most Canadian provinces and territories rely
on the pan-Canadian Oncology Drug Review (pCODR) to
provide recommendations regarding public reimbursement
of cancer drugs. The pCODR review process considers four
dimensions of value—clinical benefit, economic evalua-
tion, patient-based values and adoption feasibility—but
they do not define weights for individual decision criteria
or an acceptable threshold for any of the criteria. Given this
implicit review process, it is of interest to understand
which factors appear to carry the most weight in pCODR
recommendations using a revealed preferences approach.
Methods Using publicly available decision summaries
(n = 91) describing submissions and resulting recom-
mendations 2011–2017, we extracted ten attributes that
characterized each submission. Using logistic regression,
we identified statistically significant attributes and esti-
mated their relative impact in final recommendations.
Results Clinical aspects appear to carry the greatest weight
in the decision to reject or not reject, along with aspects of
patient value (treatments with no alternatives were less
likely to be rejected). Cost effectiveness does not appear to
play a role in the initial decision to reject or not reject but is
critical in full versus conditional approvals. There is evi-
dence of a maximum acceptable threshold of around
$Can140,000 per quality-adjusted life-year (QALY)
gained.
Conclusion A set of factors driving pCODR recommen-
dations is identifiable, supporting the consistency of the
review process. However, the implicit nature of the review
process and the difficulty of extracting and interpreting
some of the attribute levels used in the analysis suggests
that the process may still lack full transparency.
Key Points
We characterize the pan-Canadian Oncology Drug
Review (pCODR) process as two stages: a decision
to reject or not reject, followed by a decision to
recommend full or condition approval (conditional
on non-rejection).
Clinical aspects appear to carry the greatest weight in
the decision to reject or not reject, whereas value for
money had the greatest weight in full versus
conditional approvals.
Notwithstanding pCODR’s implicit review process,
there appears to be an identifiable and consistent set
of factors driving pCODR recommendations.
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1 Introduction
Health technology assessment involves the joint consider-
ation of multiple criteria in aid of specific policy decisions.
In this paper, we explore how pan-Canadian Oncology
Drug Review (pCODR) balances clinical, economic, social
and organizational criteria to make recommendations
regarding the funding of oncology drugs to drug plans
across Canada. Specifically, we evaluate the impact of the
content and quality of economic analyses and clinical
studies on recommendations to fund, not fund, or condi-
tionally fund specific cancer drugs.
The Canadian healthcare system is publicly funded from
general taxation revenues. In line with the broader feder-
alist structure, the federal government collects and pools
revenue and oversees the general legislative framework,
but allocations of monies to specific healthcare services,
including drug plans, are made at the sub-national
(provincial) level. In Canada and elsewhere, there has been
a movement to centralize the drug review process [1, 2] to
provide national recommendations to be acted on at the
sub-national level.
The pCODR was established in 2011 and is adminis-
tered alongside the broader Common Drug Review (CDR)
within the Canadian Agency for Drugs and Technologies in
Health (CADTH). While CDR is responsible primarily for
non-cancer community-based treatments, the pCODR is
responsible for cancer drugs administered in and outside of
hospitals [3, 4].
The stated objective of the pCODR review process is
‘‘to bring consistency and clarity to the assessment of
cancer drugs’’ in focusing on four explicit dimensions of
value: clinical benefit, economic evaluation (value for
money), patient-based values and adoption feasibility [5].
pCODR guidelines do not offer explicit weights for these
dimensions or a threshold that would need to be met for
any single element of the review. Each dimension is to be
discussed with reference to the uniqueness of the individual
drug, disease and context [5]. This implicit approach con-
trasts with the UK National Institute for Health and Care
Excellence (NICE), which has effectively adopted a more
explicit, though still contextual, cost-effectiveness ‘range’
[6–8].
The ambiguity of implicit approaches can provide
flexibility in exercising appropriate contextual judgement
and addressing the inherently complex nature of healthcare
priority setting [9–11]. However, ambiguity can also
adversely impact transparency, rigour and consistency and
may create an opportunity—perceived or real—for special
interest groups to unduly influence decisions [12–15].
More explicit decision weights and acceptable trade-offs
(for example, a maximum cost-effectiveness threshold)
arguably avoid some of these issues.
Given the implicit nature of the pCODR process, it is of
interest to understand how these decisions are actually
made. The processes and committees involved in the
review of drugs (cancer and otherwise), and the basis of
recommendations for reimbursement, have previously been
investigated in the literature from several angles. There are
three broad strands of this literature, focusing on (1)
comparisons of processes, (2) the assessment of regional
variations between recommendations, and (3) the factors
that appear most important in driving recommendations.
Our study contributes to this third category.
High-level comparisons of review processes between
jurisdictions show that drug reimbursement decisions are
important across healthcare systems yet vary in the struc-
tures and decision criteria used [16], process indicators
[17, 18] and resulting recommendations [19–21]. Varia-
tions are attributed to general differences between health
systems [19, 22] and insufficient economic evidence [23].
Some cross-country variations are explained by consider-
ations of therapeutic value [24], disease severity [25] and
economic considerations [22, 26, 27]. Clinical considera-
tions have been shown to be significant predictors of
funding recommendations in Canada, the UK and Poland
[28–31], with clinical uncertainty being significant in
Belgium and Wales [32, 33] and not significant in Scotland
[34]. Cost effectiveness was a significant influence on
funding recommendations in all countries except Wales
[33]. In addition, funding bodies have considered the rec-
ommendations made elsewhere [22].
We were interested in assessing the relative importance
placed on the four dimensions of value defined by pCODR
guidelines to understand the basis of their recommenda-
tions. We were also interested in testing whether there may
be unstated acceptable thresholds for some aspects, par-
ticularly around the economic dimensions. Using publicly
available information on pCODR recommendations to
date, we estimated the relative importance of individual
criteria on the likelihood of a drug receiving a positive,
negative or conditional recommendation. We did not
address the unique separation of responsibilities in Canada
between pCODR and CDR, although this issue has been
debated elsewhere in the literature [35–37].
Our study builds on the existing literature by focusing
on recommendations made by a review body that has not
previously been investigated using a revealed preferences
methodology. Our study differs from that of Rocchi et al.
[28] in that they investigated the recommendations of the
CDR, whose mandate includes the review of drugs and
therapies considered for public funding in Canada except
for oncology drugs. pCODR is a separate review body,
with a strict focus on cancer drugs.
C. Skedgel et al.
2 Methods
2.1 Data and Data Extraction
Data for this study were extracted from publicly available
reports of all recommendations made by pCODR between
2011 and 2017 [38]. These reports are prepared by the
pCODR Expert Review Committee and provide a summary
of the evidence for each of the four dimensions that are
used to guide recommendations: clinical benefit, economic
evaluation (or value for money), patient-based values and
adoption feasibility. pCODR makes three possible recom-
mendations: full approval, conditional approval or rejec-
tion. This format is consistent with many other review
bodies in that at least one intermediate level exists between
‘accept’ and ‘reject’ recommendations (e.g. restricted use,
conditional acceptance, time-limited acceptance).
Funding is recommended (full approval) if a submission
is judged to meet all four dimensions of value (clinical
benefit? value for money? patient values? adoption fea-
sibility). If a submission does not (and cannot) meet one or
more dimensions, the recommendation is to reject for
funding. However, if the committee feels that the neglected
dimension(s) could potentially be addressed by some
change, such as a reduction in price or additional clinical
evidence, then the committee can recommend a conditional
approval, pending this change or clarification. In practice,
it appears that conditional approval has been exclusively
granted pending a reduction in price.
We used an initial sample of ten summaries to identify
variables for extraction and to validate their labels. Sub-
sequently, each report was coded by two independent
reviewers. Conflicts were resolved via discussion and, if
consensus could not be reached, a deciding vote by a third
reviewer. The unit of analysis was submissions rather than
drugs, as the same drug could be submitted for more than
one indication. A particular drug–indication combination
could also be re-submitted for consideration on the basis of
new evidence or a new price following a conditional
approval. Each submission, whether initial or re-submis-
sion, was treated as an independent observation.
Within the decision summaries, we identified ten con-
sistently reported elements, which we subjectively cate-
gorized according to the pCODR decision criteria in
Table 1. We recorded observed survival with the inter-
vention and the comparator as reported in each submission.
However, different submissions reported average or med-
ian overall survival (OS), progression-free survival (PFS),
or 12-month, 24-month or 36-month survival rates. To
accommodate these different measures of clinical benefit,
we analysed survival data in terms of relative benefit,
taking the ratio of whichever statistic was reported for the
intervention and comparator groups. When more than one
survival statistic was reported, we estimated relative benefit
in this order of priority: OS, PFS, and finally x-month
survival. If there was no comparator in the submission, we
set relative survival to 1. We also added a flag indicating
whether the primary outcome of the clinical evidence was
OS, and an interaction term between clinical benefit and
the OS flag to test whether clinical outcomes reported in
terms of OS carried more weight in pCODR deliberations
than disease-free survival or PFS.
The quality of clinical evidence was assessed on the
basis of whether the submission was based on a phase III,
double-blinded randomized controlled trial with an appro-
priate control arm and was judged as methodologically
strong in the pCODR report. The severity of adverse events
was defined relative to existing treatments; a substantial
increase in the risk of an adverse event relative to the
clinical standard was coded as high, whereas similar or
lesser risks were coded as low. Submissions were consid-
ered to address an issue of ‘limited treatment options’ if no
or very few alternative treatments were available to treat
the particular condition.
Uncertainty of the economic model was judged on the
basis of comments in the economic summary as well as
whether the summary reported a specific cost-effectiveness
ratio (ICER). We used the ICER estimate judged most
plausible by pCODR economic reviewers; this was often
based on a version of the original economic model adapted
by pCODR reviewers to incorporate different assumptions
or input parameters. We divided the ICER by 10,000 to
facilitate model convergence.
Patient time and infrastructure requirements both tended
to closely correspond with whether the drug was an oral or
intravenous form of the drug. Oral drugs were associated
with less patient time, in terms of both chemotherapy ‘chair
time’ as well as travel time to a chemotherapy clinic.
Likewise, oral drugs tended to reduce the infrastructure
requirements associated with therapy, although some oral
drugs required additional testing or blood monitoring. We
coded these subjectively, on the basis of comments in the
decision summary, and—although we arbitrarily assigned
patient time to the patient values dimension and infras-
tructure to the adoption feasibility dimension—we recog-
nise there is overlap between these attributes and
dimensions. Likewise, aspects expressed in patient value
statements tended to correspond with survival benefit or
unmet need, and therefore these attributes can be seen as
measures of patient value as well as clinical benefit.
Finally, specific budget impact was not typically reported
as this was dependent on the characteristics and circum-
stances of each province, but we coded the expected budget
impact as high or low on the basis of the size of relevant
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patient population, the cost of the drug, and expected new
infrastructure or testing requirements.
2.2 Statistical Analysis
We conducted a complete-case analysis, excluding records
with missing values. We used a chi-squared bivariate test for
associations between individual attributes and the final
recommendation and used multivariate regression methods to
estimate the impact of different factors on pCODR recom-
mendations. We addressed the following two questions:
1. Which of the identified factors (and dimensions)
appear to carry the greatest weight in pCODR
recommendations?
2. Is there an implicit maximum willingness-to-pay or
cost-utility threshold in pCODR recommendations?
Table 1 Description and distribution of attributes (complete case analysis N = 91)
Variable name Description Possible values Frequency Association between recommendation and
attribute
Approved Conditional Rejected Chi2
p value
Clinical benefit
Overall
clinical
benefita
Conclusion of pERC with respect to
overall clinical benefit
1 Net benefit 62 (68%) 14 48 0 \0.001
2 Uncertain benefit 13 (14%) 0 4 9
3 No benefit 16 (18%) 0 1 15
Relative
survival gain
Survival gain relative to comparator
in the clinical study measured as
overall survival, progression free
survival, 5 year survival or 1 year
survival
1 Survival[comparator 72 (79%) 11 44 17 0.48
0 SurvivalB comparator 19 (21%) 3 9 7
Overall
survival flag
Identifies whether the clinical trial
reported OS data or a different
clinical endpoint
1 OS reported 55 (60%) 6 20 10 0.91
0 OS not reported 36 (40%) 8 33 14
Quality of
clinical
evidence
The quality of the clinical study in
terms of phase of study, and results
1 High quality 72 (79%) 12 48 12 \0.001
0 Low quality 19 (21%) 2 5 12
Severity of
side effects
Severity of adverse events (AE)
measured in relation to existing
treatment
1 Lower AE 75 (82%) 14 46 15 0.01
0 High/uncertain AE 16 (18%) 0 7 9
Economic evaluation
ICER The size of the incremental cost
effectiveness ratio in relation to a
threshold value
1 ICERC $150,000 52 (57%) 0 37 15 \0.001
0 ICER\$150,000 39 (43%) 14 16 9
ICER quality Model uncertainty (outcomes of
sensitivity analysis, lack of clarity
around methods)
1 High/unknown
uncertainty
75 (82%) 12 44 19 0.86
0 Low uncertainty 16 (18%) 2 9 5
Patient based values
Type of drug Type of drug used as a proxy for the
burden experienced by patient
1 IV 46 (51%) 8 25 13 0.74
0 Oral 45 (49%) 6 28 11
Alternatives Are alternatives available 1 No alternatives 23 (25%) 3 16 4 0.42
0 Alternatives 68 (75%) 11 37 20
Adoption feasibility
Infrastructure Additional costs of infrastructure or
testing
1 High 52 (57%) 7 29 16 0.52
0 Low 39 (43%) 7 24 8
Budget
impact
Impact estimated on the basis of
patient population size and
available alternatives
1 High/uncertain budget
impact
72 (79%) 10 41 21 0.44
0 Low budget impact 19 (21%) 4 12 3
pERC pan-Canadian Oncology Drug Review, pERC pCODR Expert Review Committee, ICER incremental cost-effectiveness ratio
aAttribute was excluded from the full model specifications
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Similar recommendations in other jurisdictions have
been analysed using binary [28, 29, 33, 34, 39–41] or
multinomial [31] regression methods or bivariate analysis
alone [42]. We addressed the first question via a two-stage
binary approach. In the first stage, the outcome of interest
was defined as rejection versus non-rejection (including
full and conditional approval). In the second stage, the
outcome of interest was full approval versus conditional
approval and was limited to alternatives that were not
rejected in the first stage.
In both stages, we used a penalized binary logistic
regression model to account for the relatively small number
of observations and the sparse contingency table. Using
this model, we systematically tested all possible main
effects combinations, as well as plausible interaction terms.
We selected a preferred specification on the basis of
Akaike’s Information Criterion corrected for small samples
(AICc) and the correspondence between the predicted and
the actual decision (predictive accuracy). We reported
estimated coefficients, p values and marginal effects for the
preferred specification in each stage.
To assess the relative importance of the included attri-
butes, we re-estimated the preferred model at each stage,
systematically excluding one attribute at a time to record
its impact on the log-likelihood (LL) and predictive accu-
racy. A greater impact on these measures was interpreted
as signalling a greater impact of the attribute on pCODR
recommendations. Attributes not included in the preferred
specifications were judged to have had little influence on
the pCODR recommendation.
The second study question was addressed via a seg-
mented linear probability model to identify any statistically
significant inflection points in the likelihood of full
approval by reported ICER. We also estimated the specific
ICER threshold at which there was a 50% probability of
approval.
All analyses were performed using R statistical soft-
ware, version 3.2.3. The binary logit model was estimated
using the BRGLM package, and segmented regression was
performed using the segmented package.
3 Results
3.1 Descriptive Statistics
Our review identified 94 unique decisions up to 30 January
2017. Of these, 15 (16%) were fully approved, 55 (59%)
were conditionally approved and 24 (26%) were rejected.
There were 81 unique drugs represented among these
decisions, with 13 submissions for more than one indica-
tion and six re-submissions. We were unable to extract a
full set of attributes for three recommendations (two did
not report an ICER, and we were unable to estimate budget
impact for one). These were excluded from the complete
case analysis, giving a final sample size of 91 recommen-
dations for the first stage of the analysis: 14 (15%) fully
approved, 53 (58%) conditionally approved and 24 (26%)
rejected. The 67 full or conditional approvals were anal-
ysed in the second stage of the analysis. The frequency
distributions of the complete case attributes are shown in
Table 1.
3.2 Statistical Analysis
The frequency distributions of the extracted attribute levels
and the significance of chi-squared tests of their association
with the final recommendation are shown in Table 1. Our
full multivariate model specification included all the attri-
butes in Table 1 except overall clinical benefit and the flag
for ICER not reported. We excluded overall clinical benefit
as it was a summary of the other attributes and was closely
correlated with the final decision. We also included four
interaction terms: relative survival gain with OS flag, rel-
ative survival gain with ICER, relative survival gain with
side effects, and available alternatives with side effects.
This full specification had an AICc of 111.95.
After systematically testing all 8191 combinations of
these variables, the specification that minimised AICc
(91.31) included a flag for high-quality clinical evidence,
the interaction between relative survival gain and low
adverse events, and the interaction between availability of
alternatives and low adverse events. This specification
correctly predicted 82% of all decisions and 50% of
rejections. The coefficients and marginal effects for this
preferred specification are summarised in Table 2. A pos-
itive coefficient indicates an increase in the likelihood of
rejection, and a negative coefficient indicates an increase in
the likelihood of approval (full/conditional approval).
This model suggested that, holding all other factors
constant, drugs with high-quality clinical evidence, better
relative survival gain, without alternatives, and with low
adverse events were less likely to be rejected. The marginal
effects suggested that a submission with high-quality
clinical evidence was 26% less likely to be rejected than a
submission with low-quality clinical evidence. This was
the only attribute that had a statistically significant influ-
ence on the recommendation. This interpretation is sup-
ported by the change in log-likelihood resulting from the
exclusion of each parameter. The quality of the clinical
evidence appeared to be approximately three times more
important than either of the other two variables.
In the second-stage analysis, estimating the likelihood of
full versus conditional approval (excluding rejections), the
full specification had an AICc of 60.52. A specification that
included only the ICER and a flag indicating a low
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incidence of adverse effects minimised AICc (Table 3).
This specification had an AICc of 27.87 and correctly
predicted 91% of full versus conditional approvals.
Submissions with a higher ICER were more likely to
receive a conditional than a full approval. Each
$Can10,000 increase in ICER was associated with a 3.3%
decrease in the likelihood of full approval. The ICER was
the only statistically significant contributor to the full
versus conditional approval recommendation. The impact
of low adverse events was not statistically significant. This
was supported by the change in log likelihood, which
suggested that the exclusion of the ICER had a much
greater impact than the exclusion of the adverse events
flag.
The predicted probability of full approval by the ICER
is plotted in Fig. 1. Submissions with an ICER\$-
Can87,500 had a[50% probability of full approval, and
there was a sharp inflection point in the probability of full
approval at an ICER of $Can140,700 per quality-adjusted
life-year (QALY) gained.
An implicit maximum acceptable cost-effectiveness
threshold around $Can140,000 per QALY gained is con-
sistent with a simple cross-tabulation of recommendations
by ICER category, shown in Table 4. All the full approvals
had a reported ICER\$Can150,000, whereas the propor-
tion of conditional approvals increased with ICERs[$-
Can100,000 per QALY.
4 Discussion
The pCODR deliberative framework [5] considers four
dimensions of value: clinical benefit, economic evaluation
(value for money), patient-based values and adoption
feasibility. If all four dimensions are judged as having been
met, the drug is recommended for funding. When one (or
more) of the four criteria is judged not to have been met,
the drug is not recommended for funding. If the unmet
criterion could potentially be met through changes to one
of the variables considered, the drug is recommended for
funding conditional on improving some aspect (most often
price). Our characterization of the decision process as a
two-stage process is consistent with this framework: an
initial decision on whether or not to reject a submission
outright and, given non-rejection, a decision on whether to
grant full or conditional approval.
Table 2 Summary of preferred specification: rejection vs. non-rejection (full/conditional approval) (n = 91)
Variable (reference level) Coefficient Standard error p value Marginal effects (%) Change in LL
Intercept 1.1361 0.5808 0.05 – –
Quality of clinical evidence (high) - 1.6961 0.6083 0.005 - 26.0 - 4.39
Rel. survival 9 AE (low) - 0.6174 0.3762 0.10 - 9.47 - 1.53
Limited treatments (yes) 9 AE (low) - 1.3095 0.9845 0.18 - 20.1 - 1.45
AE adverse event, LL Log likelihood
Table 3 Summary of preferred specification: full vs. conditional approval (n = 67)
Variable (reference level) Coefficient Standard error p value Marginal effects (%) Change in LL
Intercept 2.56218 2.38696 0.28 – –
ICER 9 10 k - 0.05537 0.01658 \0.001 - 3.3 - 22.31
Adverse events (low) 2.64817 2.15856 0.22 15.8 - 1.88
ICER incremental cost-effectiveness ratio, LL Log likelihood
Fig. 1 Predicted probability of full approval by incremental cost-
effectiveness ratio (ICER) and final recommendation
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Our first model suggested that pCODR’s decision to
reject versus approve (fully or conditionally) a submission
is driven almost exclusively by the clinical profile (quality
of the clinical evidence, relative survival gains and the
incidence of adverse events) and the consideration of
alternatives. This finding is consistent with other literature
that demonstrates the influence of clinical uncertainty
[28, 33] and clinical superiority [28–30, 32, 40] on funding
recommendations in Belgium, Canada, Poland, the UK,
and Wales. The number of alternative treatments has also
been shown to be important in Australia and Belgium
[32, 43].
Value for money, in the form of cost per QALY gained,
does not appear to play a role in the initial decision to reject
or accept, but it was a key factor in the decision over full
versus conditional approval (in non-rejected cases). There
was evidence of a maximum cost-effectiveness threshold
around $Can140,000 per QALY gained, with no submis-
sions beyond this threshold receiving full approval. Sub-
missions that reported a low incidence of adverse events
were also more likely to receive full approval.
The factors that were significant in the two models
appeared to represent three of the four dimensions con-
sidered by pCODR: clinical (quality of evidence, relative
survival gain, adverse events), economic (ICER) and
patient values (availability of alternatives). Adoption fea-
sibility, particularly as represented in terms of budget
impact, did not appear in either model. This may reflect
that budget implications are province specific and likely
play a much greater role in the provincial decision to fund a
drug. At the national review level, it is difficult to accu-
rately account for provincial budget considerations.
Notwithstanding consideration of the availability of
alternatives in pCODR recommendations, patient values
are still largely neglected in the review process. Patient
input to submissions often expresses a willingness to accept
greater risks of adverse events in exchange for longer
survival or greater treatment options. Some consideration
of a greater willingness to accept risk, or (presumably) a
greater willingness to pay for health gains, would arguably
be more relevant expressions of patient values than the
simple count of treatment alternatives, but they are not
included in the current review process. Appropriate meth-
ods for measuring and incorporating such patient values
and preferences merits further research.
Subjectivity in coding the qualitative factors, and a
relative lack of variability in many of them, are key limi-
tations of the study. As noted, the decision summaries were
largely descriptive, and interpretations of aspects such as
unmet need, the severity of adverse events, the quality of
clinical and economic evidence, and patient values were
unavoidably subjective—for us as well as for the pCODR
committee members. This risk was managed with standard
qualitative coding techniques, including the consistent
application of a priori coding criteria (emerging from the
initial sample of ten reports), the use of two independent
reviewers, and the resolution of conflicts in consultation
with a third reviewer. The statistical analysis was also
limited by a relatively small number of observations, which
may lead to a sparse contingency table and unrealistic
parameter estimates. This is mitigated by our use of a
penalized model and by emphasising the change in log-
likelihood rather than marginal effects as a measure of
relative importance.
5 Conclusion
Among the four dimensions of value highlighted in
pCODR guidelines (clinical, economic, adoption feasibil-
ity, and patient values), clinical aspects appeared to carry
the greatest weight in the decision to reject or not reject,
along with aspects of patient value (treatments with no
alternatives were less likely to be rejected). Cost effec-
tiveness did not appear to play a direct role in the initial
decision to reject or not reject but is critical in full versus
conditional approvals. There was also evidence of a max-
imum acceptable threshold around $Can140,000 per
QALY gained. These results are plausible and have a face
validity consistent with anecdotal descriptions of the
Table 4 pCODR
recommendations by
incremental cost-effectiveness
ratio
$Can Full approval Conditional approval Rejection All
\$50,000 5 0 2 7
$50–100,000 6 5 2 13
$100–150,000 3 12 5 20
$150–200,000 0 14 8 22
[$200,000 0 23 7 30
Unreported 1 1 0 2
All 15 55 24 94
Chi-squared = 39.63, p\0.001
ICER incremental cost-effectiveness ratio, pCODR pan-Canadian Oncology Drug Review
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pCODR review process. Together, they suggest there is an
identifiable set of factors driving pCODR decisions, sup-
porting the consistency of the review process despite the
absence of explicit decision weights or thresholds. How-
ever, the implicit nature of the review process, and the
difficulty of extracting and interpreting some of the attri-
bute levels used in the analysis, suggests that the process
may still lack transparency.
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